Table 1.
Blood pressure of rat preparation
| Baseline BP | BP after intravitreal injection(s) | |
|---|---|---|
| 3 μl saline vehicle (n = 5) | 127 ± 5 | 129 ± 6 |
| 10 μl saline vehicle (n = 5) | 117 ± 5 | 119 ± 5 |
| Fluorocitrate vehicle (n = 3) | 120 ± 5 | 122 ± 7 |
| Apyrase (n = 4) | 122 ± 8 | 123 ± 7 |
| AOPCP (n = 3) | 110 ± 8 | 108 ± 9 |
| ATPγS (n = 3) | 110 ± 8 | 113 ± 12 |
| Suramin (n = 3) | 128 ± 3 | 126 ± 3 |
| isoPPADS (n = 3) | 115 ± 8 | 114 ± 5 |
| TNP-ATP (n = 4) | 102 ± 6 | 105 ± 6 |
| NF023 (n = 4) | 125 ± 4 | 120 ± 4 |
| A438079 (n = 3) | 129 ± 5 | 127 ± 5 |
| AZ10606120 (n = 3) | 124 ± 4 | 122 ± 6 |
| Fluorocitrate (n = 4) | 119 ± 4 | 121 ± 3 |
| Fluorocitrate, endothelin-1 and NF023 (n = 4) | 126 ± 3 | 124 ± 3 |
A430879, 3-[[5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine; AOPCP, α,β-methylene ADP; AZ10606120, N-[2-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-5-quinolinyl]-2-tricyclo[3.3.1.13,7]dec-1-ylacetamide dihydrochloride; BP, blood pressure; isoPPADS, pyridoxalphosphate-6-azophenyl-2′,5′disulphonic acid; NF023, 8,8′-[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis-1,3,5-naphthalene-trisulphonic; TNP-ATP, 2′,3′-O-(2,4,6-trinitrophenyl)-ATP. Mean arterial BP in mmHg. BP was measured before intravitreal injection and after injection, when steady-state arteriole diameter measurements were made. For all experiments, there were no significant differences in BP before and after injection(s).